Company Overview and News

14
It May Be Better To Avoid Sanofi

2018-09-06 seekingalpha
Since September 5, 2017, Sanofi (NYSE:SNY) stock has been down by almost 15%. And most of this downfall stems from investors concerned about the company’s future growth trajectory, considering that its top-selling diabetes drug Lantus, which was earning as much as $7.0 billion annually, went off-patent in 2015. Another blockbuster drug, Plavix, also went off-patent in 2012.
MYL AMGN BCNQY MDCO LLY CVS UNH SNY ALNY

28
Your Daily Scoop: Anifrolumab Flunks, Aquestive Approved, Vertex's CRISPR Trial In Germany

2018-09-03 seekingalpha
Discussion: AstraZeneca (AZN) announced failure of a Phase 3 trial of its anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (‘SLE). The drug failed to achieve a statistically valid reduction in disease activity at month 12 as measured by a scale called SRI4. Reduction in SRI4 value was the primary endpoint of the trial. Shares slipped marginally by 1% in the negative news.
VRTX QDEL AQST AZN PTLA AUPH ARWR CRSP GSK CADILAHC CDLYY MYL 532321 AUP AZN IMMU BMS JNJ BGNE NVS

140
9 High-Risk Stocks to Buy for Massive Rewards

2018-08-31 investorplace - 5
Slow and steady wins the race, as the old adage goes. But slow and steady can be a bit boring. Investors looking for stocks to buy, as a rule, should focus on high-quality, and preferably, lower-risk issues.
SGMS CHKVP CHGG CHKDH CHKVZ CHKDG MYL CHKDJ CHKDP SDRL CSCO FSLR CSIQ SUP GWP IBM SPLK CKRGZ EVRI SFL CHKWZ GWPH CHK CHK.WI TSLA

22
Why Teva’s Outlook Is Mixed

2018-08-23 investorplace - 3
Teva Pharmaceutical (NYSE:TEVA) perfectly illustrates the dangers of trading volatile biotech stocks. Last year was particularly horrendous for TEVA stock. The company’s shares lost almost half their market value. It was also one of those stories that got worse as you read more about it.
BRK.A MYL AGN TEVA NYTAB

25
Your Daily Pharma Scoop: Audentes's New Designation, Esmya Rejected, Agilent Approved

2018-08-23 seekingalpha - 1
Discussions: Audentes Therapeutics' (BOLD) AT132 receives FDA designation of a Regenerative Medicine Advanced Therapy (‘RMAT). The therapy is indicated for treatment of X-linked myotubular myopathy (‘XLMTM). RMAT is in many ways similar to the Breakthrough Therapy status and allows accelerated review of a drug along with more frequent interaction with the FDA during the development stage. The therapy has already acquired Rare Pediatric disease, Fast track and Orphan Drug Designation in the U.
IRWD ALPMF AZN NURO GSK CANF BOLD GBHPF 4503 MYL ALPMY AGN MRK GHG GSK DCTH TNXP DCTHD BMY ALNY

 
EpiPen News: FDA Extends Expiration Dates Due to Shortage

2018-08-22 investorplace
In the latest EpiPen news, the Food and Drug Administration (FDA) has extended the expiration dates of the popular allergy medication due to a shortage of the injection.
MYL

16
Are Teva and Mylan Entering an EpiPen Price War to Zero?

2018-08-16 247wallst
Mylan N.V. (NASDAQ: MYL) has had a stranglehold on the market for EpiPen, but this is all changing after the U.S. Food and Drug Administration (FDA) approved Teva Pharmaceutical Ltd. (NYSE: TEVA) for a generic version of it.
MYL TEVA

22
Heat Biologics Stock Is a Worthwhile, Speculative Bet

2018-08-15 investorplace - 2
Investors still waiting for Heat Biologics (NASDAQ:HTBX) to trade at a market cap of $100 million will have to wait longer. The stock surged to above $4 a share in May, but that proved temporary.
MYL TEVA BMY HTBX

9
6 Stocks Defying the Bull Market With Multiple Analyst Downgrades and Price Target Cuts

2018-08-09 247wallst - 2
The morning roll call of analyst upgrades and downgrades included about 20 companies this Thursday. There are many companies that are falling outside of the strong trends of this earnings season. With about 80% of the S&P 500 having reported earnings for the second quarter of 2018, roughly 70% of those companies are beating expectations. It’s what’s happening with that other 30% of companies that is leaving investors scratching their heads.
SOJA SO ACAD MYL EXTR ELF DLPH

12
Top Analyst Upgrades and Downgrades: Applied Materials, Extreme Networks, Mylan, NXP, Roku, Seagate, Yelp, Zynga and More

2018-08-09 247wallst - 1
Stocks were indicated to open marginally higher after a weaker producer price index report calmed some inflation fears. Earnings season has been quite strong, with more than 70% of the companies exceeding expectations and 80% of the S&P 500 having reported, and the S&P 500 is quite close to all-time highs again. Still, the volatility in 2018 has created less rewarding trades by buying the dips, which had been so reliable in prior years.
WFCNP EPC YELP ITG ELF ZNGA MYL SCGLF AMAT MS WFC SCGLY CBB ACAD TRI EXTR GLE

 
MYL / Mylan N.V. 10-Q (Quarterly Report)

2018-08-08 sec.gov
Document
MYL

 
MYL / Mylan N.V. FORM 8-K/A (Current Report)

2018-08-08 sec.gov
Form 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
MYL

 
Why Mylan Is Paying the Price for Q2

2018-08-08 247wallst
When Mylan N.V. (NASDAQ: MYL) reported its most recent quarterly results before the markets opened on Wednesday, the company posted $1.07 in earnings per share (EPS) and $2.81 billion in revenue. Consensus estimates from Thomson Reuters had called for $1.22 in EPS and $2.96 billion in revenue, and the second quarter of last year had EPS of $1.10 on $2.96 billion in revenue.
MYL TRI

 
MYL / Mylan N.V. 8-K (Current Report)

2018-08-08 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MYL

43
Disney, Snap, Roku and More Earnings Coming This Week

2018-08-06 247wallst
Second-quarter earnings reporting season is beginning to wind down, but there are still plenty of companies reporting and helping set the direction for the markets. We have already seen strong earnings from many companies pushing all three of the major averages higher since the start of this season. If the markets want to keep up their momentum, companies will have to keep hitting their targets.
YELP CVS DDD MYL MTCH DBX ODP KORS ROKU TRI DIS SNAP

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to MYL / Mylan N.V. on message board site Silicon Investor.

Amylinu0027s Projected Annual EPS Amylinu0027s Projected Annual EPS Amylinu0027s Projected Annual EPS AMYLIN PHARM. AMYLIN PHARM. AMYLIN PHARM.
Mylan Labs Mylan Labs Mylan Labs AMLN: Amylin Pharmaceuticals AMLN: Amylin Pharmaceuticals AMLN: Amylin Pharmaceuticals
MYL -Mylan MYL -Mylan MYL -Mylan Mylex Mylex Mylex
MVL.VSE - Mylan Ventures Info MVL.VSE - Mylan Ventures Info MVL.VSE - Mylan Ventures Info
CUSIP: N59465109